JAC Advance Access published online on January 13, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh536
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Microbiology Department, School of Medicine, Universidad Complutense, Madrid, Spain
* To whom correspondence should be addressed. In order to explore the pharmacodynamic need for continuous versus intermittent (three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic computerized device was used to simulate concentrations of ceftazidime in human serum after 6 g/day. Efficacy was measured as the capability of simulated concentrations over time to reduce initial inoculum against four strains of Pseudomonas aeruginosa. MICs of the strains matched NCCLS breakpoints: one susceptible strain (MIC=8 mg/L), two intermediate strains (MIC=16 mg/L) and one resistant strain (MIC=32 mg/L). Cmax was 119.97±2.53 mg/L for intermittent bolus and Css (steady-state concentration) was 40.38±0.16 mg/L for continuous infusion. AUC0-24 was similar for both regimens ( Against the susceptible and intermediate strains, no differences were found between both regimens with These results stress the importance of optimizing t >MIC, even at peri-MIC concentrations, of ceftazidime against resistant strains. Local prevalence of resistance justifies, on a pharmacodynamic basis, electing for continuous infusion versus intermittent administration.
Received June 18, 2004
Revised October 4, 2004
Accepted November 15, 2004
Original article
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model
José Prieto, E-mail: jprieto{at}med.ucm.es
Abstract 
950 mg·h/L). Inhibitory quotients were three times higher for the intermittent administration whereas t > MIC was higher for continuous infusion (100%) versus intermittent administration (99.8%, 69% and 47.6% for the susceptible, intermediate and resistant strains, respectively).
3 log10 reduction from 8 to 24 h. Against the resistant strain, only the continuous infusion achieved this bactericidal activity in the same time period, minimizing the differences between resistant and susceptible strains. Significantly higher initial inoculum reduction at 32 h was obtained for the continuous versus the intermittent administration (83.35% versus 38.40%, respectively).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Hubert, E. Le Roux, T. Lavrut, B. Wallaert, P. Scheid, D. Manach, D. Grenet, I. Sermet-Gaudelus, S. Ramel, C. Cracowski, et al. Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3650 - 3656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Moriyama, S. A Henning, M. M Neuhauser, R. L Danner, and T. J Walsh Continuous-Infusion {beta}-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria Ann. Pharmacother., July 1, 2009; 43(7): 1324 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lamoth, T. Buclin, C. Csajka, A. Pascual, T. Calandra, and O. Marchetti Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies Antimicrob. Agents Chemother., February 1, 2009; 53(2): 785 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nomura, N. Morikawa, K. Ikawa, K. Ikeda, Y. Fujimoto, D. Shimizu, K. Taniguchi, K. Shimura, Y. Kanbayashi, T. Komori, et al. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis J. Antimicrob. Chemother., April 1, 2008; 61(4): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Henrichfreise, I. Wiegand, I. Luhmer-Becker, and B. Wiedemann Development of Resistance in Wild-Type and Hypermutable Pseudomonas aeruginosa Strains Exposed to Clinical Pharmacokinetic Profiles of Meropenem and Ceftazidime Simulated In Vitro Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3642 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pea, P. Viale, D. Damiani, F. Pavan, F. Cristini, R. Fanin, and M. Furlanut Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3550 - 3553. [Abstract] [Full Text] [PDF]
|
|